Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Percheron Therapeutics ( (AU:PER) ) has issued an update.
Percheron Therapeutics has disclosed that director James Garner increased his direct holding in the company by purchasing 1 million fully paid ordinary shares on-market between 17 and 19 December 2025 for a total consideration of $8,500. Following the transaction, Garner holds 53.5 million ordinary shares along with a substantial portfolio of unquoted options, a move that signals continued insider confidence and may be closely watched by shareholders and market participants as an indicator of management’s outlook on the company’s prospects.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an Australia-listed biotechnology company operating in the therapeutics sector. It is focused on developing pharmaceutical treatments, with its securities, including fully paid ordinary shares and unquoted options, traded on the ASX, reflecting an investor base attuned to early-stage and growth-oriented life sciences businesses.
Average Trading Volume: 2,314,609
Technical Sentiment Signal: Sell
Current Market Cap: A$8.7M
For an in-depth examination of PER stock, go to TipRanks’ Overview page.